A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Abroad (travel likely)Recruiting

Conditions

Obstructive Hypertrophic Cardiomyopathy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Local Institution - 0001, Seoul, South Korea
Novotech Laboratory Korea Co., Ltd., Seoul, South Korea
Contact: Study coordinator (South Korea Generic Country) · 0000000000

Study leads

Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)

Cardiomyopathy

Abroad (travel likely)Recruiting

Minato-ku, Japan

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

Hypertrophic Cardiomyopathy

Abroad (travel likely)Recruiting

Beijing, China · Beijing, China

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Obstructive Hypertrophic Cardiomyopathy

Abroad (travel likely)Recruiting

Anchorage, United States · Tucson, United States

Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Abroad (travel likely)Recruiting

Bollington, United Kingdom